The stock of Curis, Inc. (NASDAQ:CRIS) is a huge mover today! About 967,585 shares traded hands or 16.82% up from the average. Curis, Inc. (NASDAQ:CRIS) has risen 90.40% since March 7, 2016 and is uptrending. It has outperformed by 82.80% the S&P500.
The move comes after 9 months negative chart setup for the $462.33M company. It was reported on Oct, 10 by Barchart.com. We have $2.85 PT which if reached, will make NASDAQ:CRIS worth $50.86 million less.
Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on November, 14. They expect $-0.11 EPS, down 175.00% or $0.07 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Curis, Inc. for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.
Curis, Inc. (NASDAQ:CRIS) Ratings Coverage
Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. TH Capital maintained the shares of CRIS in a report on Monday, November 9 with “Buy” rating. The rating was downgraded by Zacks on Monday, September 21 to “Sell”. FBR Capital initiated the shares of CRIS in a report on Tuesday, August 11 with “Outperform” rating. As per Monday, November 9, the company rating was maintained by Roth Capital. The stock of Curis, Inc. (NASDAQ:CRIS) earned “Hold” rating by Zacks on Tuesday, September 1.
According to Zacks Investment Research, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.”
Insitutional Activity: The institutional sentiment increased to 1.78 in Q2 2016. Its up 0.88, from 0.9 in 2016Q1. The ratio is positive, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
Walleye Trading Llc reported 4,550 shares or 0% of all its holdings. Blackrock Fund holds 4.59M shares or 0% of its portfolio. Amalgamated Retail Bank, a New York-based fund reported 11,792 shares. Focused Wealth Management reported 188,350 shares or 0.14% of all its holdings. New York State Common Retirement Fund reported 101,500 shares or 0% of all its holdings. Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 88,921 shares. Moreover, Baker Bros Lp has 0.03% invested in Curis, Inc. (NASDAQ:CRIS) for 2.00 million shares. National Bank & Trust Of New York Mellon Corp, a New York-based fund reported 357,246 shares. Janney Montgomery Scott Ltd Limited Liability Company holds 0.01% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 169,400 shares. First New York Ny holds 0% or 12,000 shares in its portfolio. Geduld E E accumulated 0.02% or 10,000 shares. The Switzerland-based Credit Suisse Ag has invested 0% in Curis, Inc. (NASDAQ:CRIS). The New Jersey-based Jacobs Levy Equity has invested 0.01% in Curis, Inc. (NASDAQ:CRIS). Royal Bancorp Of Canada holds 0% or 811,129 shares in its portfolio. Fincl Bank Of America Corp De holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 29,930 shares.
Insider Transactions: Since May 26, 2016, the stock had 0 buys, and 2 selling transactions for $51,750 net activity. KAITIN KENNETH I had sold 15,000 shares worth $26,400 on Thursday, May 26. Shares for $25,350 were sold by GREENACRE MARTYN D on Friday, May 27.
CRIS Company Profile
Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.